NICOSIA, Cyprus, February 19, 2018 /PRNewswire/ --
New Neonatal Birth Unit is
a World First to Improve Health Outcomes of Babies
Born by C-Section
Today, Monday February 19 2018,
NnBU Holdings Ltd (https://nnbu.io) announces it is set to raise
€15million in an ICO for the world's first neonatal birth unit,
using blockchain technology, which will help deliver healthy
outcomes for babies born by Caesarean-section (also known as
C-section).
(Photo:
https://mma.prnewswire.com/media/643336/NnBU_Neonatal_Birth_Unit.jpg
)
The conceptual design for the NnBU device (https://nnbu.io) has
been completed and patented. The funds raised will be used to
develop the machine and market it to hospitals and clinics
internationally. This unique unit is designed to massage the
torso of a C-section newborn and simulate the positive stresses of
natural birth. As most C-section babies are born asleep, the NnBU
device also focuses light on the baby's fontanel in order
to create a comfortable waking process for the newborn
baby.
The inventors of the new medical device are working in
partnership with the highly prestigious Fraunhofer Institute of
Manufacturing, Engineering and Automation based in Stuttgart, Germany
(https://www.ipa.fraunhofer.de/en.html) and medical device
developers DMTpe (https://www.dmtpe.com/de/).
It is estimated that 40 million C-section deliveries take place
globally each year. The key factor when looking at this
market is the extraordinary growth in the number of C-section
births in recent decades. Figures from the Organization for
Economic Cooperation and Development (OECD) show that the average
C-section rate in the 35-member countries was 19.8% in 2000 but had
risen to 27.9% in 2015.
Crucially, numerous studies have shown that children born by
C-section have a higher incidence of medical issues than those who
are born naturally. The University of
Edinburgh found that babies delivered by C-section have a
59% higher risk of obesity under the age of 5, and a 21% increased
risk of asthma under the age of 12*.
Other research studies have also found links between C-sections
and allergies**, type 1-diabetes and celiac disease***.
C-sections are a risk factor for these medical issues because
the positive stresses of a natural birth are necessary to stimulate
a baby's immune system to fully prepare them for life.
The NnBU baby care unit will incorporate three functions that
will operate within the blockchain. The first will be a
system to ensure that only suitably qualified medical staffers who
have been trained in the use of the device will physically be able
to operate it. The second will be the security feature which
ensures that only qualified medical personnel will be able to carry
out maintenance work on the device. Thirdly, the exact
treatment received by each baby will be recorded, and subject to
the permission of the parents and the laws on this sensitive
subject, over time there will be an invaluable research tool
relating to children who have had C-section deliveries.
The token pre-sale ICO from NnBU starts on Monday March 19 2018 and runs for six days, with
the main sale starting on March 26
and running till April 25. The
token is a passive income token which entitles the holders to a
share of revenue from NnBU Holdings Limited. Assuming the
target contribution of €15million is reached, token holders are
expected to receive each year a figure equal to 12.5% of the
Company's sales. Uniquely for an ICO, all participants will
be offered a legal contract enforceable in a court of law in
addition to a smart contract. The minimum contribution for
token holders will be 1 Ethereum (ETH).
Based on NnBU projections and assuming that these are achieved,
the 12.5% of revenue share creates rates of return to investors in
the level of highly profitable investment deals in conventional
industries, similar to private equity. Further information can be
found in the NnBU white paper on the company's website
(https://nnbu.io).
NnBU CEO Frédéric Vo Van said, "I
myself was born through caesarean section. In my thirties I
realised I was developing symptoms which studies have shown are
connected to conditions typically experienced by a significant
proportion of people born by C-section. This is a superb
initiative that allows people to get involved with a far-reaching,
long-sighted, technological innovation that is set to improve
health outcomes for many children for several decades to come."
Links:
NnBU Website: https://nnbu.io
NnBU Whitepaper:
https://nnbu.io/wp-content/uploads/2018/02/white-paper-nnbu.pdf
NnBU Telegram group: https://t.me/NnBUOfficial
NnBU Twitter: https://twitter.com/NnBUBABY
BitcoinTalk:
https://bitcointalk.org/index.php?topic=2963342.0
Frédéric Vo Van is available for
interview. High resolution imagery and charts available on
request.
About NnBU
Headquartered in Cyprus, NnBU
HOLDINGS LIMITED is an innovation company which has developed a
specialized medical device. Specifically, NnBU focuses on the
care of babies who are delivered through C-section.
The neonatal birth unit is currently in its development stage and
is supported by medical professionals globally. The company has
received a patent covering this design and the process parameters
which is now registered under the German Patent and Trademark
Office. The fact that the patent has been granted indicates that
there is no similar device in the market.
NnBU is the registered trademark of NnBU Holdings Limited.
About the ICO
The Company will mint 60 million tokens. Of these, 7.5
million tokens (equivalent to 12.5% of the total) will be
immediately locked up in a Token Reserve. The 15 million
tokens offered in the pre-sale will be on sale on Monday, March 19, 2018, and will remain on sale
until Sunday, March 25 or until all
those tokens have been allocated, if earlier. The ICO sale
event, covering 37.5 million tokens, will start on Monday, March 26, 2018, being the day following
the end of the pre-sale event period, and close on Wednesday, April 25, 2018 or when all the tokens
are allocated, if earlier. Tokens will be allocated in both
the pre-sale and sale events on a "first come, first served"
basis.
Full instructions as to how to go through all the relevant
processes, which will include full Anti-Money Laundering (AML) and
Know Your Client (KYC) procedures, are to be found on the NnBU
Website (https://nnbu.io).
The minimum contribution amount per investment transaction is
set to 1 Ethereum (ETH) and this limit will be hardcoded into the
smart contract code. This means that the smart contract system will
reject investments below this threshold.
About Frédéric Vo
Van
NnBU co-founder and CEO, Frédéric Vo
Van is an experienced executive with a track record of
successful growth strategies in global organisations and across
diverse global territories. Previously, Frédéric worked as a
business development and international affairs director at
Lufthansa, a Deutscher Index (DAX - German Stock Index) listed
company.
Based in Berlin, Germany, he is
a specialist in new business and the global strategic development
of companies. His work has taken him around the globe and has
included many highly successful international initiatives.
Frédéric became involved with NnBU following his interest in the
invention. When he moved to Germany, aged 31, he developed allergies he
had not previously experienced and he also became more sensitive to
cold weather. While researching, he found that those, like
him, born through C-section, were also likely to develop allergies
and similar problems in later life.
Media information provided by Famous Publicity.
For further information please contact Adam Betteridge at adam@famouspublicity.com,
Mary-Jane Rose at
mary-jane@famouspublicity.com or Tina
Fotherby at tina@famouspublicity.com
Sources:
* - PLOS Medicine Journal, January
23 2018: 'Long-term risks and benefits associated with
caesarean delivery for mother, baby, and subsequent pregnancies:
Systematic review and meta-analysis.'
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002494
** - Springer Semin Immunopathol, February 2004: 'Effects of intestinal microflora
and the environment on the development of asthma and allergy.'
https://www.ncbi.nlm.nih.gov/pubmed/15007630
*** - Karolinska Institutet,
July 2 2014: 'Cesarean section may
cause epigenetic
changes.' http://ki.se/en/news/cesarean-section-may-cause-epigenetic-changes